Kristin Fathe, Silvia Ferrati, Daniel Moraga-Espinoza, Ashkan Yazdi and Hugh D.C. Smyth Pages 2501 - 2521 ( 21 )
Background: Delivery of pharmacologically active compounds to the lung for systemic effects is well known and recently has entered a new era with several products achieving regulatory approval. This review focuses on the barriers to pulmonary delivery of biologics. Methods: Lessons learned from the development of recently approved products will be reviewed to shed light on the current challenges that are faced when developing biological products for inhaled delivery. Results: The text and tables presented herein consolidate the current data and ongoing research regarding biological, inhaled products. Conclusion: With this basis, we also review the future prospects for pulmonary delivery of biologics for systemic delivery and how the biological and physical barriers may be overcome.
Systemic pulmonary delivery, biologics, inhalation devices.
, , , , Division of Pharmaceutics, University of Texas at Austin, Austin, USA.